Danaher subsidiaries Beckman Coulter, Cepheid, and Leica Biosystems will be working together with external partners to focus on existing disease areas.

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% ...

By 2050, over 1.7 million Canadians are projected to be living with dementia. This represents an increase of 187 per cent ...

WORTHINGTON — Though the group is no stranger to performing on stage, JD Productions will take its first bows at ...

TORONTO -- Biomarkers pointing to increased risk for Alzheimer's disease were markedly reduced with the investigational cholesteryl ester transfer protein (CETP) inhibitor obicetrapib relative to ...

A computer program predicts with more than 75% accuracy who will develop dementia in the near future.

The FDA greenlit multiple new drugs this month and issued some notable label expansions including for Eli Lilly’s Kisunla.

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

Daily doses of obicetrapib over 52 weeks led to significant reductions in plasma p-tau217 and other Alzheimer’s disease ...

An experimental drug appears to reduce the risk of Alzheimer’s-related dementia in people destined to develop the disease in ...

Long-term extension data presented at the Alzheimer's Association International Conference showed amyloid plaque ...

A new study shows that the way amyloid proteins—implicated in Alzheimer's disease—assemble into fibrils can be significantly ...